Short Interest in PicoCELA Inc. (NASDAQ:PCLA) Decreases By 76.2%

PicoCELA Inc. (NASDAQ:PCLA) was the target of a significant decline in short interest during the month of August. As of August 14th, there was short interest totaling 102,426 shares, a decline of 76.2% from the July 30th total of 429,834 shares. Based on an average daily volume of 587,318 shares, the short-interest ratio is currently 0.2 days. Approximately 269.5% of the shares of the company are sold short.

PicoCELA Stock Performance

Shares of NASDAQ:PCLA traded down $0.17 during midday trading on Thursday, hitting $7.30. 38,419 shares of the stock traded hands, compared to its average volume of 585,445. PicoCELA has a one year low of $1.35 and a one year high of $19.61. The business’s 50 day moving average is $5.65 and its two-hundred day moving average is $4.40.

Hedge Funds Weigh In On PicoCELA

A hedge fund recently bought a new stake in PicoCELA stock. XTX Topco Ltd purchased a new stake in shares of PicoCELA Inc. (NASDAQ:PCLA) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 44,648 shares of the company’s stock, valued at approximately $72,000. XTX Topco Ltd owned approximately 0.16% of PicoCELA at the end of the most recent reporting period.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. Wall Street Zen raised shares of PicoCELA to a “hold” rating in a research report on Saturday, July 25th. Weiss Ratings upgraded PicoCELA from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, August 17th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, PicoCELA currently has an average rating of “Sell”.

PicoCELA Company Profile

PicoCELA, Inc is a clinical-stage biotechnology company focused on the development of next-generation vaccines and immunotherapies based on its proprietary self-assembling protein nanoparticle platform. The company engineers functionalized, virus-like protein particles designed to present disease-relevant antigens in their native conformation, with the goal of eliciting potent B-cell and T-cell responses. PicoCELA’s platform enables the rapid design and production of vaccine candidates against infectious diseases as well as antigen-specific immunotherapies for certain cancers.

The company’s pipeline includes vaccine programs targeting SARS-CoV-2 and other respiratory pathogens, leveraging its nanoparticle scaffolds to display full-length viral spike proteins or other key antigens.